首页> 外国专利> METHOD AND SYSTEM FOR REDUCING THE LIKELIHOOD OF DEVELOPING LIVER CANCER IN AN INDIVIDUAL DIAGNOSED WITH NON-ALCOHOLIC FATTY LIVER DISEASE

METHOD AND SYSTEM FOR REDUCING THE LIKELIHOOD OF DEVELOPING LIVER CANCER IN AN INDIVIDUAL DIAGNOSED WITH NON-ALCOHOLIC FATTY LIVER DISEASE

机译:减少非酒精性脂肪肝疾病个体诊断中发展为肝癌的可能性的方法和系统

摘要

A method for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease involves providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of Lactobacillus species, and administering fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual. In certain embodiments, monoacylglycerolacyltransferase-3 (MGAT3) synthesis is inhibited to lower triacylglycerol (TAG) production, while in others, expression of diacylglycerolacyltransferase-2 (DGAT-2) is inhibited. The beneficial bacteria are preferably modified to produce increased amounts of butyrate and may also be encapsulated in a frangible enclosure. Levels of Roseburia are preferably increased while the levels of Akkermansia spp. in the individual's gut microbiome are reduced. In other embodiments, a therapeutically effective amount of a bacterial formulation comprising Faecalibacterium prausnitzii is administered, or a composition comprising modified L. reuteri bacteria having the ability to survive conditions in the duodenum or jejunum of the individual's small intestine. Other embodiments include the administration of a bacterial formulation comprising at least one of Coprococcus, Veillonella, Roseburia, Bifidobacterium, Faecalibacterium prausnitzii and Prevotella.
机译:在诊断为非酒精性脂肪肝的个体中,降低罹患肝癌的可能性的方法包括在个体的肠道中提供有益细菌群,这些有益菌群选自乳酸杆菌物种,向个体施用纤维以在个体的肠道中维持治疗有效量的有益细菌。在某些实施方案中,单酰基甘油糖基乳糖基转移酶-3(MGAT3)的合成被抑制以降低三酰基甘油(TAG)的产生,而在其他实施方案中,二酰基甘油基糖基laclacyltransferase-2(DGAT-2)的表达被抑制。优选地,有益细菌被修饰以产生增加量的丁酸酯,并且也可以被封装在易碎的外壳中。 玫瑰红的水平最好增加,而 Akkermansia spp的水平最好增加。在个体的肠道微生物组中减少。在其他实施方案中,施用治疗有效量的包含普拉伊法氏杆菌的细菌制剂或包含修饰的L的组合物。罗伊特氏细菌具有在个体小肠十二指肠或空肠中生存的能力。其他实施方案包括给予细菌制剂,所述细菌制剂包含协球菌,韦永氏菌,玫瑰菌,双歧杆菌,普氏嗜藻杆菌和普氏杆菌中的至少一种。

著录项

  • 公开/公告号US2020121743A1

    专利类型

  • 公开/公告日2020-04-23

    原文格式PDF

  • 申请/专利权人 JOSEPH E. KOVARIK;

    申请/专利号US201916722117

  • 发明设计人 JOSEPH E. KOVARIK;

    申请日2019-12-20

  • 分类号A61K35/747;A61K35/745;A61K35/742;A61K9;

  • 国家 US

  • 入库时间 2022-08-21 11:24:11

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号